# Alamar Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alamar-biosciences

- Industry: Biotechnology
- Headquarters: Fremont, US
- Website: www.alamarbio.com
- Total disclosed funding: $222M
- Latest round: Series C (Feb 26, 2024)
- Investors on record: 6

## About

Founded in 2018 and based in California, US, Alamar Biosciences, Inc. operates as a biotechnology company for developing treatments for cancers. The company was co-founded by CEO Dr. Yuling Luo, COO Dr. Steve Chen, and Vice President of Technology Dr. Yiyuan Yin. In January 2026, Alamar Biosciences, Inc. raised USD 50 million in venture debt funding from T. Rowe Price Investment Management, Inc., Braidwell LP., Illumina Ventures and Sands Capital. Alamar Biosciences is a precision proteomics company that brings both sensitivity and parallel scale to proteomic analysis, which is systematic identification and quantification of the complete complement of proteins (the proteome) of a biological system such as cells, tissues, organs, biological fluids, or organisms. The company's two proprietary technology platforms, NULISA™ and Attobody™, work seamlessly with advances in genomics to achieve single-digit attomolar detection sensitivity, surpassing sensitive protein detection technology. The company will use the January 2026 funding to accelerate its commercial objectives in precision medicine and advance early disease detection efforts.

## Funding rounds

- Series C, Feb 26, 2024, $128M — Sands Capital Alternatives
- Series B, Sep 8, 2021, $80M — Qiming Venture Partners, Illumina Ventures, Samsara BioCapital, Morningside, Sherpa Healthcare Partners
- Series B, May 26, 2020, $14M — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Morningside (https://capitalatlas.ai/funds/morningside) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series C